| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-24171 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-20840 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-21039 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-21017 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-20943 | |||
![Immunohistochemistry-Paraffin: CD23/Fc epsilon RII Antibody (FCER2/8237R) [NBP3-23614] - Formalin-fixed, paraffin-embedded human tonsil stained with CD23/Fc epsilon RII Antibody (FCER2/8237R). HIER: Tris/EDTA, pH9.0, 45min. 2°C: HRP-polymer, 30min. DAB, 5min.](http://images.novusbio.com/fullsize/nbp3-23614_rabbit-cd23-fc-epsilon-rii-mab-fcer2-8237r-2412025872316.jpg "Immunohistochemistry-Paraffin: CD23/Fc epsilon RII Antibody (FCER2/8237R) [NBP3-23614] - Formalin-fixed, paraffin-embedded human tonsil stained with CD23/Fc epsilon RII Antibody (FCER2/8237R). HIER: Tris/EDTA, pH9.0, 45min. 2°C: HRP-polymer, 30min. DAB, 5min.")
![Flow Cytometry: KLRG1 Antibody (2F1) [NBP1-28115] - C57BL/6 mouse splenocytes were stained with Hamster Anti-Mouse KLRG1-FITC (SB Cat. 1807-02) and Mouse Anti-Mouse NK1.1-PE (SB Cat. No. 1805-09).](http://images.novusbio.com/fullsize/KLRG1-Antibody-2F1-Flow-Cytometry-NBP1-28115-img0001.jpg "Flow Cytometry: KLRG1 Antibody (2F1) [NBP1-28115] - C57BL/6 mouse splenocytes were stained with Hamster Anti-Mouse KLRG1-FITC (SB Cat. 1807-02) and Mouse Anti-Mouse NK1.1-PE (SB Cat. No. 1805-09).")
![Flow Cytometry: CD4 Antibody (GC1A) [NBP2-60890] - Obtained with caprine leukocytes](http://images.novusbio.com/fullsize/CD4-Antibody-GC1A-Flow-Cytometry-NBP2-60890-img0001.jpg "Flow Cytometry: CD4 Antibody (GC1A) [NBP2-60890] - Obtained with caprine leukocytes")
![Neutralization: IL-21 Antibody (MT216G/21.3m) [NBP3-18290] - The neutralizing capacity and ND50 was determined using ELISA andELISpot. A) HEK cells were transfected to express the IL-21 activation pathway with alkaline phosphatase as a reporter. Cells were stimulated in the presence of recombinant human IL-21 (10 ng/ml) with or without serial dilutions of NBP3-18290. After overnight incubation, enzyme activity was measured in ELISA. B) Human peripheral blood mononuclear cells (PBMC) were incubated with recombinant IL-21 (10 ng/ml) with or without serial dilutions of NBP3-18290. After 4 days the IgG-secreting B cells were quantified by ELISpot.](http://images.novusbio.com/fullsize/IL-21-Antibody-MT216G-21-3m-Neutralization-NBP3-18290-img0001.jpg "Neutralization: IL-21 Antibody (MT216G/21.3m) [NBP3-18290] - The neutralizing capacity and ND50 was determined using ELISA andELISpot. A) HEK cells were transfected to express the IL-21 activation pathway with alkaline phosphatase as a reporter. Cells were stimulated in the presence of recombinant human IL-21 (10 ng/ml) with or without serial dilutions of NBP3-18290. After overnight incubation, enzyme activity was measured in ELISA. B) Human peripheral blood mononuclear cells (PBMC) were incubated with recombinant IL-21 (10 ng/ml) with or without serial dilutions of NBP3-18290. After 4 days the IgG-secreting B cells were quantified by ELISpot.")